A database of FDA approved therapeutic peptides and proteins
Details of Th1216 which contains 1 entries. |
| Entry 1 | |
| (1) Primary information | |
|---|---|
| ID | 1826 |
| ThPP ID | Th1216 |
| Therapeutic Peptide/Protein Name | Anthrax immune globulin human |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIa |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 24.3 days |
| Description | Anthrax immune globulin is a human immune globulin that is used in combination with antibiotics to treat anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and edema toxins. This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins. |
| Indication/Disease | Anthrax immune globulin is indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs. |
| Pharmacodynamics | NA |
| Mechanism of Action | Polyclonal anthrax immune globulin is a passive immunizing agent that neutralizes anthrax toxin by binding to Protective Antigen (PA) to prevent PA-mediated cellular entry of anthrax edema factor and lethal factor. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins. |
| Toxicity | The most common adverse reactions to Anthrasil observed in >5% of healthy volunteers in clinical trials were headache, infusion site pain and swelling, nausea, and back pain. |
| Metabolism | NA |
| Absorption | Peak levels were reached immediately after infusion and then declined over the duration of study (84 days). Mean activity remained above the lower limit of quantitation (5 milliunits per mL) over the entire 84-day post-dose period for the three doses studied. Cmax was found to be 83.0 mU/mL while Tmax was found to be 0.116 days. |
| Volume of Distribution | 5714.8 mL |
| Clearance | 174.2 mL/day |
| Categories | Plasma derivative |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Bazedoxifene may increase the thrombogenic activities of Anthrax immune globulin human.; Chlorotrianisene may increase the thrombogenic activities of Anthrax immune globulin human; Conjugated Equine Estrogens may increase the thrombogenic activities of Anthrax immune globulin human; Dienestrol may increase the thrombogenic activities of Anthrax immune globulin human; Diethylstilbestrol may increase the thrombogenic activities of Anthrax immune globulin human; Estradiol may increase the thrombogenic activities of Anthrax immune globulin human; Estriol may increase the thrombogenic activities of Anthrax immune globulin human; Estrone may increase the thrombogenic activities of Anthrax immune globulin human; Ethinyl Estradiol may increase the thrombogenic activities of Anthrax immune globulin human; Genistein may increase the thrombogenic activities of Anthrax immune globulin human. |
| Target | Protective antigen |
| Information of corresponding available drug in the market | |
| Brand Name | ANTHRASIL |
| Company | Cangene Corporation |
| Brand Discription | Anthrax immune globulin belongs to a group of medicines known as immunizing agents. |
| Prescribed for | It is indicated for the treatment of inha lational anthrax in adult and pediatric patients in 35 combination with appropriate antibacterial drugs |
| Chemical Name | NA |
| Formulation | 60 [iU]/35mL |
| Physcial Appearance | Liquid |
| Route of Administration | Intravenous |
| Recommended Dosage | The initial dose of ANTHRASIL for the treatment of inhalational anthrax in adults in combination with appropriate antimicrobial therapy is 420 units |
| Contraindication | History of anaphylactic or severe systemic reaction to human immune globulins |
| Side Effects | Hypersensitivity reactions including anaphylaxis |
| Useful Link | https://www.drugs.com/cons/anthrasil.html , https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM439812.pdf |
| PubMed ID | 23979731 |
| 3-D Structure | N.A. |